Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
634 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01984697 | A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010) | completed | Phase 3 | 1,518 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT01021748 | A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) | completed | Phase 1 | 63 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2018 |
| clinicaltrials |
| NCT00687440 | A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | completed | Phase 2 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 3, 2018 | clinicaltrials |
| NCT01395758 | Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 96 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00092547 | A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) | completed | Phase 3 | 1,781 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 20, 2018 | clinicaltrials |
| NCT02083484 | Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 26, 2018 | clinicaltrials |
| NCT00599755 | Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3) | completed | Phase 1 | 68 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 16, 2018 | clinicaltrials |
| NCT00871910 | Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | completed | Phase 1 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 23, 2017 | clinicaltrials |
| NCT01473095 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | completed | Phase 1 | 120 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT01078220 | Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031) | completed | — | 189,629 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT00638963 | Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)(STOP) | terminated | Phase 2 | 6 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00686725 | Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) | completed | Phase 4 | 99 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00266799 | The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) | completed | Phase 3 | 210 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00266812 | Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED) | terminated | Phase 2 | 35 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00423150 | Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) | terminated | Phase 2 | 86 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00727961 | A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) | completed | Phase 4 | 58 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT02762721 | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | completed | — | 131 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 2 | Jun 8, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00424554 | Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) | completed | Phase 2 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00457418 | High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) | completed | Phase 1 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00550771 | Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) | completed | Phase 2 | 181 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00604968 | Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059) | terminated | Phase 4 | 25 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | terminated | Phase 2 | 53 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00687323 | Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)(TALL) | completed | Phase 2 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00091572 | Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) | completed | Phase 3 | 859 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2017 | clinicaltrials |
| NCT01234857 | A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | completed | Phase 2 | 115 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 31, 2017 | clinicaltrials |
| NCT00034697 | Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) | terminated | Phase 2 | 24 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 23, 2017 | clinicaltrials |
| NCT00684463 | Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED) | completed | Phase 4 | 59 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00335075 | Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) | completed | Phase 3 | 151 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00687011 | Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594) | completed | Phase 4 | 118 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00780039 | A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | completed | Phase 2 | 58 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00783393 | SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) | completed | Phase 2 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT00060476 | Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) | completed | Phase 3 | 15,000 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT00076856 | Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) | completed | Phase 2 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT00831545 | Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | completed | Phase 2 | 162 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT00092183 | An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) | completed | Phase 4 | 866 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 5, 2017 | clinicaltrials |
| NCT00092196 | Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) | completed | Phase 3 | 820 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 5, 2017 | clinicaltrials |
| NCT00090220 | A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) | completed | Phase 3 | 3,819 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2017 | clinicaltrials |
| NCT00411749 | V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2017 | clinicaltrials |
| NCT00378560 | V501 Efficacy Study in Women Aged 18 to 26 (V501-027) | completed | Phase 2 | 1,021 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 17, 2017 | clinicaltrials |
| NCT00496626 | An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) | completed | Phase 3 | 600 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 17, 2017 | clinicaltrials |
| NCT01062074 | GARDASIL Reexamination Study (V501-059) | completed | — | 3,605 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 17, 2017 | clinicaltrials |
| NCT00126451 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) | terminated | Phase 2 | 16 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 10, 2017 | clinicaltrials |
| NCT00097929 | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) | completed | Phase 2 | 18 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT00686543 | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) | completed | Phase 4 | 75 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT00750178 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008) | completed | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT00759109 | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | completed | Phase 3 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 5, 2017 | clinicaltrials |
| NCT00732641 | Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | completed | Phase 3 | 244 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials